

Individual short-term responses to antiplatelet therapy vary

March 30 2015



(HealthDay)—For patients with ischemic heart disease, responses to antiplatelet therapy (APT) vary between pre-discharge and one week after discharge from hospital, according to a study published online March 21 in the *Journal of Thrombosis and Haemostasis*.

Vikram Khanna, B.M., from the University of Southampton in the United Kingdom, and colleagues examined whether responses to APT varied significantly over time. Forty patients on dual APT underwent simultaneous assay with VerifyNow and Short thrombelastography (s-TEG) before and at four time points over six months following [hospital discharge](#). The authors also measured serum thromboxane B₂ (TXB₂) levels.

The researchers found that aspirin response units by VerifyNow and serum TXB₂ levels remained stable over time. Compared with pre-discharge, arachidonic acid-mediated platelet aggregation with s-TEG increased at one week (P

"In conclusion, this study demonstrates important variability in responses to APT within individuals between pre-discharge and one week but not thereafter," the authors write. "The design of future strategies to assess individual responses for tailored therapy need to take this into account."

One author disclosed financial ties to medical device companies, including Haemonetics Corporation, which supported the study.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Individual short-term responses to antiplatelet therapy vary (2015, March 30) retrieved 28 April 2024 from
<https://medicalxpress.com/news/2015-03-individual-short-term-responses-antiplatelet-therapy.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--